October 21, 2014 | IonMed announced that it has received CE Mark clearance for its Bioweld1™ cold plasma system for surgical incision closure. Bioweld1 is the first system in the emerging field of plasma medicine that was designed for use in operating rooms as a viable alternative to surgical staples, sutures and sealants. “With the CE Mark clearance of Bioweld1, our first system, we have achieved important validation for our technology, a key milestone for the company, and a significant step towards commercialization,” said Shai Levanon, CEO of IonMed. IonMed is based in Yokneam, Israel and develops and commercializes non-thermal plasma technology to enhance surgical wound closure and healing.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments